Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential [Corrigendum]
{"title":"Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential [Corrigendum]","authors":"A. Chiricozzi, C. De Simone, B. Fossati, K. Peris","doi":"10.2147/ptt.s225339","DOIUrl":null,"url":null,"abstract":"Figure 3 Bimekizumab efficacy in treating psoriatic arthritis patients, assessed in a phase II trial. Clinical outcomes in psoriatic arthritis patients after 12-week therapy with placebo or different bimekizumab dosages. Abbreviations: ACR, American College of Rheumatology; BKZ, bimekizumab; CASPAR, Classification Criteria for Psoriatic Arthritis; N, number; pts, patients; Q4, every 4 weeks; R, randomization; SJC, swollen joint count; TJC, tender joint count; tot., total; w, weeks. 64 mg BKZ Q4 for 12 w","PeriodicalId":20796,"journal":{"name":"Psoriasis : Targets and Therapy","volume":"24 1","pages":"73 - 74"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psoriasis : Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/ptt.s225339","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Figure 3 Bimekizumab efficacy in treating psoriatic arthritis patients, assessed in a phase II trial. Clinical outcomes in psoriatic arthritis patients after 12-week therapy with placebo or different bimekizumab dosages. Abbreviations: ACR, American College of Rheumatology; BKZ, bimekizumab; CASPAR, Classification Criteria for Psoriatic Arthritis; N, number; pts, patients; Q4, every 4 weeks; R, randomization; SJC, swollen joint count; TJC, tender joint count; tot., total; w, weeks. 64 mg BKZ Q4 for 12 w
图3 Bimekizumab治疗银屑病关节炎患者的疗效，在II期试验中评估。银屑病关节炎患者在安慰剂或不同比美珠单抗剂量治疗12周后的临床结果缩写:ACR, American College of Rheumatology;BKZ bimekizumab;银屑病关节炎分型标准CASPAR;N,数量;分,患者;Q4，每4周;R,随机化;SJC，肿胀关节计数;TJC，投标接头计数;合计。,总;w,周。64mg BKZ Q4 12 w
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
